SCHEMBL1648916

SCHEMBL1648916

CCOC(=O)c1c(CS(=O)(=O)c2cccc(Cl)c2)ccc(-c2ccoc2)c1OC

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 1/20 0.42
METAP2 P50579 4/20 0.40
HIF1A Q16665 1/20 0.37
MAPT P10636 2/20 0.36
MAPK1 P28482 1/20 0.36
ALOX5 P09917 4/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
ALDH1A1 P00352 1/20 0.35
HCRTR2 O43614 1/20 0.35
PTGES O14684 1/20 0.34
CHRNA7 P36544 1/20 0.34
FABP4 P15090 1/20 0.33
FABP5 Q01469 1/20 0.33
TP53 P04637 1/20 0.33
TUBB4A P04350 1/20 0.33
TUBB P07437 1/20 0.33
TUBA3C P0DPH7 1/20 0.33
TUBA1B P68363 1/20 0.33
TUBA4A P68366 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1648187 0.89 METAP2 (0.48) METAP2FABP4FABP5TUBB4ATUBB
SCHEMBL1648344 0.89 METAP2 (0.45) PPARGMETAP2MAPTMAPK1MEN1
SCHEMBL1648424 0.84 PPARG (0.40) PPARGMETAP2HIF1AMAPTMAPK1
SCHEMBL1648177 0.82 PPARG (0.42) PPARGMETAP2HIF1AMAPTMEN1
SCHEMBL1648096 0.82 METAP2 (0.44) PPARGMETAP2MAPTALDH1A1FABP4
SCHEMBL1648150 0.82 METAP2 (0.44) PPARGMETAP2FABP4FABP5TUBB4A
SCHEMBL1648321 0.82 CYP1A2 (0.36) PPARGMETAP2MAPTMAPK1MEN1
SCHEMBL1648313 0.82 PPARG (0.39) PPARGMETAP2MAPTMAPK1MEN1
SCHEMBL1648175 0.81 MEN1 (0.42) HIF1AMAPTMAPK1ALOX5MEN1
SCHEMBL1648590 0.81 METAP2 (0.49) PPARGMETAP2FABP4FABP5TUBB4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2486004-B1 SULPHONE COMPOUNDS FOR USE IN THE TREATMENT OF OBESITY ZAFGEN INC (US) 2017-05-03 EP disclosed
EP-2486004-B1 SULPHONE COMPOUNDS FOR USE IN THE TREATMENT OF OBESITY ZAFGEN INC (US) 2017-05-03 EP disclosed
US-20160051531-A1 SULPHONE COMPOUNDS AND METHODS OF MAKING AND USING SAME ZAFGEN INC (US) 2016-02-25 US disclosed
US-9067905-B2 Sulphone compounds and methods of making and using same ZAFGEN, INC. (US) 2015-06-30 US disclosed
US-9067905-B2 Sulphone compounds and methods of making and using same ZAFGEN, INC. (US) 2015-06-30 US disclosed
US-9067905-B2 Sulphone compounds and methods of making and using same ZAFGEN, INC. (US) 2015-06-30 US disclosed
US-20130053364-A1 Sulphone Compounds and Methods of Making and Using Same ZAFGEN, INC. 2013-02-28 US disclosed
US-20130053364-A1 Sulphone Compounds and Methods of Making and Using Same ZAFGEN, INC. 2013-02-28 US disclosed
US-20130053364-A1 Sulphone Compounds and Methods of Making and Using Same ZAFGEN, INC. 2013-02-28 US disclosed
EP-2486004-A2 SULPHONE COMPOUNDS AND METHODS OF MAKING AND USING SAME Zafgen Corporation (US) 2012-08-15 EP disclosed
WO-2011044506-A2 SULPHONE COMPOUNDS AND METHODS OF MAKING AND USING SAME ZAFGEN CORPORATION (US) 2011-04-14 WO disclosed
WO-2011044506-A2 SULPHONE COMPOUNDS AND METHODS OF MAKING AND USING SAME ZAFGEN CORPORATION (US) 2011-04-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160051531-A1 SULPHONE COMPOUNDS AND METHODS OF MAKING AND USING SAME METAP2, DNPEP, STS PPARG 1735/4885METAP2 1/4885HIF1A 2610/4885
US-20130053364-A1 Sulphone Compounds and Methods of Making and Using Same METAP2, DNPEP, STS PPARG 1735/4885METAP2 1/4885HIF1A 2610/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.